Award
National Heart, Lung, and Blood Institute 5R01HL163172-05
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity
Recipient
Beth Israel Deaconess Medical Center, Boston, MA, United States
Award Amount
$633,596.00
Ceiling
$633,596.00
Awarded
May 18, 2026
Identifier
5R01HL163172-05
Research project funded to study hemopexin as a biomarker and therapeutic target for anthracycline-induced cardiac toxicity using clinical and mouse model data.
Description
This project aims to investigate the role of hemopexin (HPX) as a biomarker and potential therapeutic pathway for anthracycline-induced cardiotoxicity, particularly related to doxorubicin (Adriamycin®). The study involves human patient cohorts and mouse models to understand heme metabolism's impact on cardiac toxicity and explore HPX's protective effects.